SCHEMBL6544771

SCHEMBL6544771

C[N]C(=O)c1cccc(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 4/20 0.49
HTT P42858 2/20 0.49
HPGD P15428 2/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
KDM4E B2RXH2 2/20 0.47
POLB P06746 2/20 0.47
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47
SLC6A2 P23975 2/20 0.46
PKM P14618 1/20 0.46
CHRNA1 P02708 1/20 0.46
CHRNG P07510 1/20 0.46
ITGA5 P08648 1/20 0.46
CHRNB1 P11230 1/20 0.46
CHRNB2 P17787 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17366091 0.82 PARP1 (0.59) PARP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL7987660 0.79 PARP1 (0.52) PARP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL9509034 0.79 PARP1 (0.52) PARP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL10802915 0.78 PARP1 (0.59) PARP1SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL10792089 0.77 PARP1 (0.53) PARP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL23931574 0.77 PARP1 (0.63) PARP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL54859 0.77 PARP1 (0.63) PARP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL17187940 0.77 PARP1 (0.63) PARP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL3169530 0.76 PARP1 (0.68) PARP1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL3173817 0.76 PARP1 (0.68) PARP1ALDH1A1HTTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014121036-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME DEUTERX, LLC (US) 2014-08-07 WO disclosed
US-20140221369-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME DEUTERX, LLC (US) 2014-08-07 US disclosed
EP-1022272-B1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS SANKYO CO (JP) 2004-05-26 EP disclosed
US-6432993-B1 BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS SANKYO COMPANY, LIMITED (JP) 2002-08-13 US disclosed
EP-1022272-A1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS Sankyo Company Limited (JP) 2000-07-26 EP disclosed
EP-0833633-A4 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 1999-03-24 EP disclosed
EP-0833633-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1998-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221369-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SRD5A2, PPARD, SRD5A1 PARP1 3978/4885SMN1; SMN2 2291/4885MEN1 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.